Bimeda Announces Acquisition of Grupo Unipharm Veterinary Portfolio
Bimeda is pleased to announce its acquisition of the Grupo Unipharm veterinary medicine portfolio, consisting of 25 licensed veterinary products and over 150 licenses. The acquisition will further strengthen Bimeda's presence in Central America, which is regarded as a region with significant growth potential.
Carlos Porragas, Bimeda Director for Latin America, commented; 'it is with great pleasure that we announce the acquisition of Grupo Unipharm's licensed veterinary medicinal product portfolio. The Central American region is one with significant potential for long-term sustainable growth, and increasing our presence here is a critical part of Bimeda's LATAM commercial strategy. The acquired portfolio of Unipharm veterinary products, perfectly complements Bimeda's existing product portfolio and allows us to present a complete product portfolio for cattle to the region.'The acquired portfolio consists of an impressive range of high quality and well-known brands across various product categories, including antimicrobials, anti-parasitics, wound repair medicines, vitamins, minerals and hormones. Leading brands such as Unicil Veterinario, Neo-Sept and Univit will complement Bimeda's already extensive portfolio of animal health products in the region.
As part of the acquisition, Bimeda will benefit from Grupo Unipharm's established commercial structure, distribution channel and logistics network, giving enviable access to six Central American markets. Bimeda in turn will use their decades of experience in the animal health industry to optimise the potential of the product range.
Porragas added, 'As a global veterinary pharmaceutical company that has been serving our customers around the world for over half a century, Bimeda is perfectly placed to ensure that this quality product range achieves its true potential within Central America and beyond. With decades of experience building a global supply chain and distribution network, we are looking forward to using Bimeda expertise to ensure customers in the region benefit from continuity of supply of this extensive product offering.'
Dr René Domínguez, Director of Exports for Latin America, noted, 'we are truly excited about this acquisition and look forward to applying Bimeda's technical and marketing expertise to support the future growth of the range and to provide unrivalled technical support to our customers. Simultaneously, we will remain future focused and will evaluate which of the more than 150 acquired licenses will feed into Bimeda's new product pipeline.'
As part of the acquisition, Bimeda will benefit from Grupo Unipharm's established commercial structure, distribution channel and logistics network, giving enviable access to six Central American markets. Bimeda in turn will use their decades of experience in the animal health industry to optimise the potential of the product range.
Porragas added, 'As a global veterinary pharmaceutical company that has been serving our customers around the world for over half a century, Bimeda is perfectly placed to ensure that this quality product range achieves its true potential within Central America and beyond. With decades of experience building a global supply chain and distribution network, we are looking forward to using Bimeda expertise to ensure customers in the region benefit from continuity of supply of this extensive product offering.'
Dr René Domínguez, Director of Exports for Latin America, noted, 'we are truly excited about this acquisition and look forward to applying Bimeda's technical and marketing expertise to support the future growth of the range and to provide unrivalled technical support to our customers. Simultaneously, we will remain future focused and will evaluate which of the more than 150 acquired licenses will feed into Bimeda's new product pipeline.'